Evolution of antihypertensive combined therapy: from depressin of academician A. L. Myasnikov to modern multi-component drugs

The article shows the historical background to the emergence and subsequent development of combined antihypertensive therapy from creation of a multi-component drug to modern fixed combinations as the most effective approach in the treatment of hypertension (HTN). The authors consider that Russian scientist therapist academician of the USSR Academy of medical Sciences A. L. Myasnikov, has priority in the development of fixed drug combination concept, created depressin powder. The development of pharmacology as a science and the achievements in pharmaceutical technologies contributed to the expansion of possible drugs combination for HTN treatment, and the discovery of new diverse pathophysiological mechanisms implemented in this pathology led to the understanding of the need for combined drugs in clinical practice. The advantages of combination HTN therapy versus monotherapy include rapid achievement of the target blood pressure level, low frequency of tachyphylaxis, longer-lasting antihypertensive effect, no need to change drugs, higher compliance, effective organoprotection and cardiovascular risk reduction, positive and/or neutral effects on the main parameters of metabolism, reduced frequency and severity of side effects. Taking into account these facts, as well as the wide prevalence of HTN in the population, its high medical and social significance, the key role in atherosclerosis, it is necessary to develop new combined domestic drugs for the treatment of HTN and their inclusion in the list of vital medicines, increasing the availability of these drugs for the population on the basis of preferential programs.